China · Delayed Price · Currency is CNY BGI Genomics Statistics
Total Valuation
BGI Genomics has a market cap or net worth of CNY 14.92 billion. The enterprise value is 12.40 billion.
| Market Cap | 14.92B |
| Enterprise Value | 12.40B |
Important Dates
The last earnings date was Saturday, August 22, 2026.
| Earnings Date | Aug 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BGI Genomics has 383.85 million shares outstanding. The number of shares has increased by 1.59% in one year.
| Current Share Class | 383.85M |
| Shares Outstanding | 383.85M |
| Shares Change (YoY) | +1.59% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 15.20% |
| Float | 219.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 144.00 |
| PS Ratio | 3.86 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 202.84 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.81 |
| Quick Ratio | 2.50 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.26 |
| Interest Coverage | -14.34 |
Financial Efficiency
Return on equity (ROE) is -6.60% and return on invested capital (ROIC) is -8.19%.
| Return on Equity (ROE) | -6.60% |
| Return on Assets (ROA) | -2.54% |
| Return on Invested Capital (ROIC) | -8.19% |
| Return on Capital Employed (ROCE) | -5.24% |
| Weighted Average Cost of Capital (WACC) | 7.92% |
| Revenue Per Employee | 1.08M |
| Profits Per Employee | -160,627 |
| Employee Count | 3,580 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 4.87 |
Taxes
In the past 12 months, BGI Genomics has paid 63.68 million in taxes.
| Income Tax | 63.68M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.73% in the last 52 weeks. The beta is 0.68, so BGI Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -27.73% |
| 50-Day Moving Average | 37.97 |
| 200-Day Moving Average | 42.57 |
| Relative Strength Index (RSI) | 47.53 |
| Average Volume (20 Days) | 14,167,948 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BGI Genomics had revenue of CNY 3.86 billion and -575.04 million in losses. Loss per share was -1.38.
| Revenue | 3.86B |
| Gross Profit | 1.28B |
| Operating Income | -482.18M |
| Pretax Income | -530.51M |
| Net Income | -575.04M |
| EBITDA | -42.04M |
| EBIT | -482.18M |
| Loss Per Share | -1.38 |
Balance Sheet
The company has 3.16 billion in cash and 527.94 million in debt, with a net cash position of 2.63 billion or 6.86 per share.
| Cash & Cash Equivalents | 3.16B |
| Total Debt | 527.94M |
| Net Cash | 2.63B |
| Net Cash Per Share | 6.86 |
| Equity (Book Value) | 8.63B |
| Book Value Per Share | 20.23 |
| Working Capital | 3.66B |
Cash Flow
In the last 12 months, operating cash flow was 73.57 million and capital expenditures -491.12 million, giving a free cash flow of -417.55 million.
| Operating Cash Flow | 73.57M |
| Capital Expenditures | -491.12M |
| Depreciation & Amortization | 440.14M |
| Net Borrowing | -307.08M |
| Free Cash Flow | -417.55M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 33.18%, with operating and profit margins of -12.49% and -14.89%.
| Gross Margin | 33.18% |
| Operating Margin | -12.49% |
| Pretax Margin | -13.74% |
| Profit Margin | -14.89% |
| EBITDA Margin | -1.09% |
| EBIT Margin | -12.49% |
| FCF Margin | n/a |
Dividends & Yields
BGI Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.59% |
| Shareholder Yield | -1.59% |
| Earnings Yield | -3.85% |
| FCF Yield | -2.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BGI Genomics has an Altman Z-Score of 5.12 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.12 |
| Piotroski F-Score | 4 |